IEFM
RXRX icon

IQ EQ Fund Management’s Recursion Pharmaceuticals RXRX Stock Holding History

IQ EQ Fund Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.56M Buy
2,604,317
+46,914
+2% +$156K 0.61% 52
2026
Q1 		$7.85M Buy
2,557,403
+153,285
+6% +$592K 0.6% 57
2025
Q4 		$9.83M Buy
2,404,118
+629,123
+35% +$3.12M 0.68% 45
2025
Q3 		$8.66M Buy
1,774,995
+863,910
+95% +$4.54M 0.59% 50
2025
Q2 		$4.61M Buy
911,085
+523,848
+135% +$2.57M 0.41% 78
2025
Q1 		$2.05M Buy
387,237
+186,767
+93% +$1.36M 0.24% 115
2024
Q4 		$1.36M Buy
200,470
+118,118
+143% +$794K 0.16% 148
2024
Q3 		$543K Buy
82,352
+42,101
+105% +$302K 0.06% 253
2024
Q2 		$302K Buy
+40,251
New +$351K 0.03% 274

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

IQ EQ Fund Management's RXRX Position: Q2 2026 in Review

IQ EQ Fund Management increased its Recursion Pharmaceuticals (RXRX) stake by 1.8% in Q2 2026, buying an estimated $156K and bringing the position to 2,604,317 shares worth $9.56M. The position accounts for 0.61% of the portfolio, ranked #52.

IQ EQ Fund Management first reported a position in RXRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $9.83M in Q4 2025. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • IQ EQ Fund Management held 2,604,317 shares of Recursion Pharmaceuticals worth $9.56M as of Q2 2026.
  • IQ EQ Fund Management bought 46,914 Recursion Pharmaceuticals shares in Q2 2026, an estimated $156K.
  • Recursion Pharmaceuticals made up 0.61% of IQ EQ Fund Management's portfolio in Q2 2026, its #52 holding.
  • IQ EQ Fund Management first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • IQ EQ Fund Management's Recursion Pharmaceuticals position peaked at $9.83M in Q4 2025.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on IQ EQ Fund Management's 13F filing for Q2 2026, filed 31 Jul 2026.